[Anomalies of cellular immunity in Graves' disease treated by synthetic antithyroid drugs: effects on prognosis].
The involvement of humoral immunity mechanism in etiology of Graves' disease was observed for the first time in 1956. Twenty years later cellular auto-immune dysfunction was also described. To day, there is evidence for suppressor T cell deficiency and decrease in T suppressor lymphocytes in Graves' disease and cell mediated immunity might be one of the most important point in the pathogenesis of Graves disease. For the future, cellular auto-immune dysfunction might be used to predict the evolution of the disease and to choice the best therapeutic scheme.
D013956:Antithyroid Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology*; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D006684:HLA-DR Antigens / Q000032:analysis / Q000276:immunology; D015803:HLA-DR3 Antigen; D006801:Humans; D007111:Immunity, Cellular; D007958:Leukocyte Count; D011379:Prognosis; D012008:Recurrence; D013601:T-Lymphocytes / Q000473:pathology; D006377:T-Lymphocytes, Helper-Inducer / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000473:pathology
D013956:Antithyroid Agents; D006684:HLA-DR Antigens; D015803:HLA-DR3 Antigen
Anomalies de l'immunité cellulaire dans la maladie de Basedow traitée par antithyroïdiens de synthèse: incidence sur le pronostic.